Tucotuzumab celmoleukin Uses, Dosage, Side Effects and more
Tucotuzumab celmoleukin is under investigation in clinical trial NCT00016237 (Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous Treatment).
| Trade Name | Tucotuzumab celmoleukin |
| Generic | Tucotuzumab celmoleukin |
| Tucotuzumab celmoleukin Other Names | Tucotuzumab celmoleukin |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
